Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematous
Keywords:
Systemic lupus erythematosus, Pulmonary arterial hypertension, Six-minute walk test, Serum proBNP levels, Transthoracic echocardiographyAbstract
Introduction: Pulmonary arterial hypertension (PAH) is an increasingly recognized complication of systemic lupus erythematous (SLE), which may remain undiagnosed if asymptomatic.
Objective: This study aimed to determine the correlation between echocardiographic findings of PAH and six-minute walk test (6WMT) and serum pro b-type natriuretic peptide (proBNP) level in patients with SLE.
Methods: This cross-sectional study was performed on 50 SLE patients selected from patients referring to the outpatient’s department of the Rheumatology Clinic at Imam Reza Hospital in Mashhad, Iran, from July 2013 through September 2014, using resting transthoracic echocardiography to estimate systolic pulmonary artery pressure (sPAP). Variables were summarized as counts and/or percentages or as mean±SD. Inter-group comparisons were made performing two-tailed Fisher’s exact test or Mann–Whitney U test, using SPSS 22.
Results: In general, five out of fifty patients were diagnosed to have PAH with sPAP>30 mmHg (range: 31-40 mmHg) based on echocardiographic findings. Spirometric parameters did not show any differences between the two groups (p>0.05), while the difference in total distance walked during six minutes and serum proBNP level between SLE patients with and without PAH was significant (P<0.05). A high correlation was found between PAP and serum proBNP level, but not between PAP and the distance walked during six-minutes in SLE patients.
Conclusion: The point prevalence of PAH in SLE patients was 10%; the significant correlation between PAP and serum proBNP level suggests that it can be used as a valuable marker for early diagnosis of asymptomatic pulmonary hypertension in patients with SLE.
References
Firestein GS, Budd R, Gabriel SE, O'Dell JR, McInnes IB. Kelley's textbook of rheumatology. New York:
Elsevier Health Sciences; 2012.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in
systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a
cohort of 1,000 patients. Medicine. 2003; 82(5): 299-308. doi: 10.1097/01.md.0000091181.93122.55.
PMID: 14530779.
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman D, et al. Mortality in systemic lupus
erythematosus. Arthritis Rheum. 2006; 54(8): 2550-7. doi: 10.1002/art.21955. PMID: 16868977.
Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary
arterial hypertension. N Engl J Med. 2002; 346(12): 896-903. doi: 10.1056/NEJMoa012212. PMID:
Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension
related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label
extensions. Ann Rheum Dis. 2006; 65(10): 1336-40. doi: 10.1136/ard.2005.048967. PMID: 16793845,
PMCID: PMC1798307.
Mirfeizi SZ, Lari S, Sahebari M, Attaran D, Pourzand H, Rafatpanah H, et al. The Relationship between
Serum Pro‐Brain Natriuretic Peptide (Pro‐BNP) Levels and Pulmonary Arterial Hypertension (PAH) in
Patients with Limited Scleroderma. J Card Thorac Med. 2014; 2(3): 181-6.
Simonson J, Schiller N, Petri M, Hellmann D. Pulmonary hypertension in systemic lupus erythematosus. J
Rheumatol. 1989; 16(7): 918-25. PMID: 2769664.
Johnson S, Gladman D, Urowitz M, Ibanez D, Granton J. Pulmonary hypertension in systemic lupus.
Lupus. 2004; 13(7): 506-9. doi: 10.1191/0961203303lu1051oa. PMID: 15352421.
Quismorio FP, Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ, et al. Immunopathologic and
clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis
Rheum. 1984; 13(4): 349-59. PMID: 6374900.
Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study
of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J.
; 129(3): 510-5. doi: 10.1016/0002-8703(95)90278-3. PMID: 7872181.
Prabu A, Patel K, Yee CS, Nightingale P, Situnayake RD, Thickett DR, et al. Prevalence and risk factors
for pulmonary arterial hypertension in patients with lupus. Rheumatology. 2009; 48(12): 1506-11. doi:
1093/rheumatology/kep203. PMID: 19671698.
Rich S. Pulmonary hypertension. In: Bonow R, Mann D, Zipes D, Libby P, editors. Braunwald's heart
disease. 9 ed. Philadelphia: Saunders; 2012. p. 1696-716.
Mukerjee D, George DS, Knight C, Davar J, Wells A, Du Bois R, et al. Echocardiography and pulmonary
function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology. 2004;
(4): 461-6. doi: 10.1093/rheumatology/keh067. PMID: 15024134.
Denton C, Cailes J, Phillips G, Wells A, Black C, Bois Rd. Comparison of Doppler echocardiography and
right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997;
(2): 239-43. doi: 10.1093/rheumatology/36.2.239. PMID: 9133938.
Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the
classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11): 1271-7. doi:
1002/art.1780251101. PMID: 7138600.
Golshan M, Nematbakhsh M, Amra B, Crapo R. Spirometric reference values in a large Middle Eastern
population. Eur Respir J. 2003; 22(3): 529-34. doi: 10.1183/09031936.03.00003603. PMID: 14516147.
Gardner RM, Hankinson JL, West BJ. Evaluating Commercially Available Spirometers. Am Rev Respir
Dis. 1980; 121(1): 73-82. doi: 10.1164/arrd.1980.121.1.73. PMID: 7352715.
Standardization of spirometry--1987 update. Statement of the American Thoracic Society. Am Rev Respir
Dis. 1987; 136(5): 1285-98. doi: 10.1164/ajrccm/136.5.1285. PMID: 3674589.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement:
guidelines for the six-minute walk test. Am J Respir Criti Care Med. 2002; 166(1): 111. doi:
1164/ajrccm.166.1.at1102. PMID: 12091180.
Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14(5): 377-81. doi:
1249/00005768-198205000-00012. PMID: 7154893.
Kamel SR, Omar GM, Darwish AF, Asklany HT, Ellabban AS. Asymptomatic pulmonary hypertension in
systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskeletal Disord. 2011; 4: 77-86. doi:
4137/CMAMD.S7667. PMID: 22084605, PMCID: PMC3201107.
Xia Y, Tu S, Hu Y, Wang Y, Chen Z, Day H, et al. Pulmonary hypertension in systemic lupus
erythematosus: a systematic review and analysis of 642 cases in Chinese population. Rheumatol Int. 2013;
(5): 1211-7. doi: 10.1007/s00296-012-2525-y. PMID: 22983159, PMCID: PMC3632720.
Farzaneh‐Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, et al. Relationship of
antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis
Rheum. 2006; 54(12): 3918-25. doi: 10.1002/art.22265. PMID: 17133599.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
